Indian drugmaker Dr Reddy’s Laboratories (BSE: 500124) has launched a generic version of Bristol Myers Squibb’s (NYSE: BMY) cancer drug Revlimid (lenalidomide).
The company said it was undertaking a “volume-limited launch,” and was eligible for 180 days of first-to-market generic drug exclusivity.
The launch comes after the company agreed with Celgene, the New York-based company acquired in 2019 by Bristol Myers, terms for a license to sell volume-limited amounts in the USA as part of a litigation settlement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze